Apremilast combined with low-dose corticosteroids for lichenoid drug eruption following programmed cell death protein 1 inhibitor and lenvatinib therapy: A case report

Programmed cell death protein 1 (PD-1) inhibitors combined with the multitarget tyrosine kinase inhibitor (TKI) lenvatinib have become a first-line treatment strategy for various malignancies and have demonstrated favorable safety profiles in prior reports, with only rare cases of drug eruption following combination therapy. Current first-line treatment for drug eruption typically involves full-dose corticosteroids. However, reports have indicated that in patients with a history of malignancy, while corticosteroids may alleviate cutaneous lesions, their use could be associated with the risk of rapid tumor progression.